DBNPA phased out: time for a future-proof alternative for effective biofilm control.
The active substance 2,2-dibromo-2-cyanoacetamide (DBNPA) has recently been placed under stricter scrutiny within European biocidal product legislation. This substance is classified as an endocrine disruptor and, as of 2023 (PT4) and 2024 (PT2), may no longer be used in most common applications, such as surface treatment in the food industry and general disinfection of installations.
For QA managers and technical service providers, disinfection is not just about effectiveness, but also about certainty and future-proofing. The phase-out of DBNPA creates uncertainty: how do you guarantee microbiological safety without legal or operational risks?
In-situ HOCl: A particularly suitable alternative
The use of in-situ generated HOCl (hypochlorous acid) offers a powerful promise to QA professionals: microbiological control without endocrine-disrupting risks, without the storage of hazardous chemicals, and with proven effectiveness against biofilm. Using this method, a solution is generated on-site and on-demand through the electrolysis of water and pure sodium chloride. The resulting agent is exceptionally effective against bacteria, viruses, yeasts, and molds, including both existing and future biofilm
DYKA has already made the switch
'Within DYKA, we focus on safety, quality, and production, and we aim to make progress every year. Thanks to Watter, we can now operate proactively instead of reactively. The consistently high water quality allows us to keep our production process stable and increase our quality.'
Unlike DBNPA, HOCl is not classified as an endocrine disruptor and is authorized in the Netherlands under the exemption regulation for in-situ generated biocides (Annex 9 Rgb, PT2 and PT4).
Get in touch with us today.
Want to discover if the Watter system is also the proven superior choice for biofilm control and prevention in your organization?